✦ LIBER ✦

Discovery of a Potent, Selective, and Orally Active Human Epidermal Growth Factor Receptor-2 Sheddase Inhibitor for the Treatment of Cancer†

✍ Scribed by Yao, Wenqing; Zhuo, Jincong; Burns, David M.; Xu, Meizhong; Zhang, Colin; Li, Yun-Long; Qian, Ding-Quan; He, Chunhong; Weng, Lingkai; Shi, Eric

Book ID: 115542942
Publisher: American Chemical Society
Year: 2007
Tongue: English
Weight: 79 KB
Volume: 50
Category: Article
ISSN: 0022-2623
DOI: 10.1021/jm061344o

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Discovery of a Potent, Selective, and Or

Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer

✍ Dorsey, Bruce D.; Iqbal, Mohamed; Chatterjee, Sankar; Menta, Ernesto; Bernardini 📂 Article 📅 2008 🏛 American Chemical Society 🌐 English ⚖ 161 KB

A-62176, a potent topoisomerase inhibito

A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2

✍ Hye-Lin Kim; Kyung-Hwa Jeon; Kyu-Yeon Jun; Yongmun Choi; Dae-Kee Kim; Younghwa N 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 495 KB

Lapatinib: A small-molecule inhibitor of

Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer

✍ Amye J. Tevaarwerk; Jill M. Kolesar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 188 KB

Discovery of BMS-846372, a Potent and Or

Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine

✍ Luo, Guanglin; Chen, Ling; Conway, Charles M.; Denton, Rex; Keavy, Deborah; Guli 📂 Article 📅 2012 🏛 American Chemical Society 🌐 English ⚖ 554 KB

ChemInform Abstract: Studies Leading to

ChemInform Abstract: Studies Leading to the Identification of ZD1839 (Iressa): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer.

✍ Keith H. Gibson; et al. et al. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 29 KB 👁 2 views

First clinical experience of orally acti

First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer

✍ Maria Giulia Zampino; Elena Magni; Cristian Massacesi; Alberto Zaniboni; Angelo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

## Abstract ## BACKGROUND. Gefitinib, an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, combined with chemotherapy, has shown efficacy as second‐line treatment for advanced colorectal cancer (CRC). Gefitinib combined with FOLFOX6 (oxaliplatin plus folinic acid